SEC Comment Letter 0000000000-23-006295 to NGM BIOPHARMACEUTICALS INC (CIK 0001426332)
NGM BIOPHARMACEUTICALS INC (CIK 0001426332)
Date: June 12, 2023 · CIK: 0001426332 · Accession: 0000000000-23-006295
AI Filing Summary & Sentiment
File numbers found in text: 333-272509
Letter
United States securities and exchange commission logo June 12, 2023 David Woodhouse Chief Executive Officer NGM Biopharmaceuticals, Inc. 333 Oyster Point Boulevard South San Francisco, CA 94080 Re:NGM Biopharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 8, 2023 File No. 333-272509 Dear David Woodhouse: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Christina T. Roupas
Show Raw Text
United States securities and exchange commission logo
June 12, 2023
David Woodhouse
Chief Executive Officer
NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
South San Francisco, CA 94080
Re:NGM Biopharmaceuticals, Inc.
Registration Statement on Form S-3
Filed June 8, 2023
File No. 333-272509
Dear David Woodhouse:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Christina T. Roupas